Fondaparinux in the management of patients with ST-elevation acute myocardial infarction

Vascular Health and Risk Management

Volumn 2, Issue 4, 2006, Pages 371-378

  Turpie, Alexander G G ^a  

^a HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Acute myocardial infarction; Anticoagulant; Arterial thrombosis; Fondaparinux; Heparin; Thrombolytic

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANISTREPLASE; CLOPIDOGREL; CREATININE; DALTEPARIN; ENOXAPARIN; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; STREPTOKINASE;

ABDOMINAL SURGERY; ACUTE HEART INFARCTION; ANTICOAGULATION; ARTERY THROMBOSIS; AUTOIMMUNE THROMBOCYTOPENIA; BLEEDING; BRAIN HEMORRHAGE; CATHETER THROMBOSIS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY REPERFUSION; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG EXCRETION; DRUG INDICATION; DRUG SAFETY; DRUG URINE LEVEL; FOLLOW UP; HEART TAMPONADE; HUMAN; KIDNEY FUNCTION TEST; LIVER TOXICITY; LUNG EMBOLISM; MORTALITY; ORTHOPEDIC SURGERY; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE HEMORRHAGE; PROTEIN BINDING; PROTEIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; ST SEGMENT ELEVATION; UNSTABLE ANGINA PECTORIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MYOCARDIAL INFARCTION; POLYSACCHARIDES; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 33846904606     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: 10.2147/vhrm.2006.2.4.371     Document Type: Review

References (39)

1. Agnelli G, Bergqvist D, Cohen AT, et al. 2005. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg, 92:1212-20.
2. Alexander KP, Chen AY, Roe MT, et al. 2005. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA, 294:3108-16.
3. Antman EM, Anbe DT, Armstrong PW, et al. 2004. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation, 110:e82-292.
4. Antman EM, Morrow DA, McCabe CH, et al. 2006. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med, 354:1477-88.
5. Bauer KA, Eriksson BI, Lassen MR, et al. 2001. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med, 345:1305-10.
6. Béguin S, Choay J, Hemker HC. 1989. The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb Haemost, 61:397-401.
7. Buller HR, Davidson BL, Decousus H, et al. 2003. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med, 349:1695-702.
8. Buller HR, Davidson BL, Decousus H, et al. 2004. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med, 140:867-73.
9. Cohen AT, Davidson BL, Gallus AS, et al. 2006. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ, 332:325-9.
10. Cohen M, Gansini GF, Maritz F, et al. 2003. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. J Am Coll Cardiol, 42:1348-56.
11. Collins R, Peto R, Baigent C, Sleight P. 1997. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med, 336:847-60.
12. Coussement PK, Bassand JP, Convens C, et al. 2001. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J, 22:1716-24.
13. Donat F, Duret JP, Santoni A, et al. 2002. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet, 41(Suppl):1-9.
14. Eagle KA, Goodman SC4 Avezum A, et al. 2002. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet, 359:373-7.
15. Eikelboom JW, Anand SS, Malmberg K, et al. 2000. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet, 355:1936-42.
16. Eikelboom JW, Mehta SR, Anand SS, et al. 2006. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation, 114:774-82.
17. Eikelboom JW, Quinlan DJ, Mehta SR, et al. 2005. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circulation, 112:3855-67.
18. Eriksson BI, Bauer KA, Lassen MR, et al. 2001. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med, 345:1298-304.
19. Herbert JM, Petitou M, Lormeau JC, et al. 1997. SR 90107/Org 31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev, 15:1-26.
20. Lassen MR, Bauer KA, Eriksson BI, et al. 2002. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet, 359:1715-20.
21. Mehta SR, Steg PG, Granger CB, et al. 2005. Arixtra Study in Percutaneous Coronary Intervention: A Randomized Evaluation (ASPIRE) Pilot Trial. Circulation, 111:1390-7.
22. Moscucci M, Fox KA, Cannon CP, et al. 2003. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J, 24:1815-23.
23. Rue SV, O'Grady K, Pieper KS, et al. 2005. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol, 96:1200-6.
24. Rao SV, O'Grady K, Pieper KS, et al. 2006. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol, 47:809-16.
25. Silber S, Albertsson P, Aviles FF, et al. 2005. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J, 26:804-47.
26. Simoons ML, Bobbink IW, Boland J, et al. 2004. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes; The Pentasaccharide in Unstable Angina (PENTUA) study. J Am Coll Cardiol, 43:2183-90.
27. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. 2006. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation, 113:e166-286.
28. Spiess BD, Royston D, Levy JH, et al. 2004. Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion, 44:1143-8.
29. [ASSENT] The Assessment of the Safety and Efficacy of New Thrombolytic Regimen (ASSENT)-3 Investigators. 2001. Efficacy and safety of tenecteplase in combination with enoxarparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet, 358:605-13.
30. Theroux P, Fuster V. 1998. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation, 97:1195-206.
31. Turpie AG 2005. The safety of fondaparinux for the prevention and treatment of venous thromboembolism. Expert Opin Drug Saf, 4:707-21.
32. Turpie AG, Bauer KA, Eriksson BI, et al. 2002a. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet, 359:1721-6.
33. Turpie AG, Bauer KA, Eriksson BI, et al. 2002b. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med, 162:1833-40.
34. Turpie AG, Gallus AS, Hock JA; Pentasaccharide Investigators. 2001. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med, 344:619-25.
35. van de Wert F, Ardissino D, Betriu A, et al. 2003. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J, 24:28-66.
36. White H; Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. 2001. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet, 358:1855-63.
37. Yusuf S, Mehta SR, Chrolavicius S, et al. 2006a. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med, 354:1464-76.
38. Yusuf S, Mehta SR, Chrolavicius S, et al. 2006b. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA, 295:1519-30.
39. Yusuf S, Mehta SR, Xie C, et al. 2005. Effects of reviparin, a low-molecular-weight heparin, on mortality reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA, 293:427-35.